<![CDATA[Artemis astronauts spotlight psychiatric medication, mental health support, and trust—revealing why psychiatry’s village mindset strengthens care, leadership, and ethics.]]>
<![CDATA[Dissect psychodermatology with experts in both fields, from the American Academy of Dermatology 2026.]]>
<![CDATA[High-potency cannabis surges; psychiatry confronts psychosis risk, dependence, and data gaps—why clinicians must guide safer use now.]]>
<![CDATA[New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.]]>
<![CDATA[Learn how therapists navigate honesty, boundaries, and transference when creative patients bring novels, paintings, or provocative images into psychotherapy.]]>
Pie Day 2026
Ellie’s Pi Day post: https://mitadmissions.org/blogs/entry/pi-day-2026-food-institute/
How Ellie orchestrated the baking of 30 pies: https://mitadmissions.org/blogs/entry/behind-the-scenes-of-thirty-pies/
<![CDATA[“While studying the CAT scan, I picture Groucho Marx as Dr. Hugo Z. Hackenbush…”
]]>
]]>
<![CDATA[Dissect psychodermatology with experts in both fields, from the American Academy of Dermatology 2026.]]>
STAT+: FDA eyes expanding testosterone therapy for libido
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hellooooo, friends. Psychedelics and testosterone are front and center today, but also we note that GLP-1’s dominance in obesity may not be as inevitable as it looks. Early animal data from GLP-1 pioneers suggest that pathways like GIP-glucagon offer effectiveness and better overall tolerability.
The need-to-know this morning
- Kailera Therapeutics raised $625 million in an initial public offering — the largest-ever Wall Street debut for a drug company. Kailera is developing obesity drugs licensed from China.
Do we even need GLP-1 anymore?
The scientists whose work helped spur the development of GLP-1-based obesity drugs are now questioning whether that target is necessary at all. Instead, they’re proposing that using GIP-glucagon as a dual target could deliver comparable — or even superior — weight loss, without the nausea and dosing limitations that come with current therapies.
The deadly consequences of ICE detention
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Earth Day is next week, meaning it’s time for one of my favorite traditions: listening to the annual 24-hour livestream of a marsh in unceded W̱SÁNEĆ territory in British Columbia.